Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) on 21 May 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release summarizing the resolutions passed at the Annual General Meeting held on 21 May 2026, including board elections, discharge of liability, dividend resolution, authorization of share issues, and long-term incentive program approvals. This fits the category “Declaration of Voting Results & Voting Rights Announcements” (DVA), which covers official results from shareholder votes at any general meeting.
2026-05-21 English
Beslut vid årsstämma i Cinclus Pharma Holding AB (publ) den 21 maj 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release detailing the resolutions passed at the Annual General Meeting on May 21, 2026, including election of directors, auditor appointments, discharge from liability, remuneration of board and auditors, result appropriation, authorization for new share issues, and approval of an incentive program. This is a formal announcement of shareholder meeting voting results, matching the definition of Declaration of Voting Results & Voting Rights Announcements.
2026-05-21 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport januari–mars 2026” (Interim report January–March 2026) and covers Q1 financial summary, consolidated and parent company financial statements, notes and CEO/board attestations. It is a comprehensive quarterly financial report rather than an announcement or transcript, matching the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is the comprehensive January–March 2026 interim report for Circlus Pharma, containing actual quarterly financial statements (net sales, EBIT, cash flow), management commentary (CEO statement), notes, and certification by the board. It covers a period shorter than a full fiscal year and is not merely an announcement or presentation, matching the definition of an Interim / Quarterly Report. Q1 2026
2026-05-13 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2025 Cinclus Pharma Holding AB (publ)', which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report, including overview, financial statements, management commentary, governance, and audit report. The content includes comprehensive financial data, management discussion, market overview, and strategic updates for the fiscal year 2025. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-16 Swedish
Notice of Annual General Meeting in Cinclus Pharma Holding AB (publ)
AGM Information Classification · 91% confidence The document is a press release titled “NOTICE OF ANNUAL GENERAL MEETING” for Cinclus Pharma Holding AB (publ), detailing the date, time, location, participation instructions, agenda items, nomination committee proposals, and board proposals for the upcoming Annual General Meeting. It is clearly an invitation/notice of the AGM rather than the meeting minutes, proxy materials, or a full annual report. This matches the definition of “AGM Information” (Code: AGM-R).
2026-04-16 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.